B Cell Lymphoma
News
FDA panel voices concerns over 2 lymphoma accelerated approvals
FDA’s ODAC committee pressed for resolution on whether 2 lymphoma drugs, long on the U.S. market, actually deliver significant benefits to...
Conference Coverage
Ocular MALT lymphoma: Radiation reduces relapse
Mortality rates from early-stage ocular MALT lymphoma are low, with relapse rates lowered by radiation therapy.
Conference Coverage
Safely skip PET2 after brentuximab in Hodgkin lymphoma?
Recent data presented at SOHO 2023 suggested that adding brentuximab vedotin to chemotherapy for Hodgkin lymphoma improves outcomes, even without...
Feature
‘Promising’ new txs for most common adult leukemia
The FDA has already approved these treatments for some other blood cancers, but chronic lymphocytic leukemia (CLL) poses unique challenges.
Feature
Lymphoma specialist to lead MD Anderson’s cancer medicine division
Dr. Christopher Flowers, a prominent African American oncologist with expertise in blood cancer and health disparity research, heads a key...
From the Journals
Antibody shows promise in preventing GVHD
In translational research that shows potential for humans, an antibody blockade of the Notch signaling pathway prevents graft-versus-host-disease...
From the Journals
CLL combo treatment: Phase-3 study inconclusive
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term...
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Article
NORD: Making Progress Through Collaboration
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.